Revenue during the year went down marginally by 0.69 percent to $179.58 million from $180.83 million in the previous year.

Operating loss for the year was $53.65 million, compared with an operating loss of $77.62 million in the previous year.

"We are pleased with the topline results reported from our two China Phase 3 trials, which are the first Phase 3 readouts for roxadustat, and bring us closer to completing our new drug application submission in China. With our partners AstraZeneca and Astellas, we are making steady progress in Phase 3 clinical development worldwide for roxadustat in CKD anemia, and continue to expect filing of our U.S. NDA in 2018," said Thomas B. Neff, FibroGen's Chief Executive Officer. "This year, we are expanding development activities for roxadustat into oncology-related anemias. We are also anticipating important clinical milestones for pamrevlumab, or FG-3019. We began the year with the presentation and publication of promising clinical results in pancreatic cancer, and expect to report data from our placebo-controlled Phase 2 trial in idiopathic pulmonary fibrosis in the third quarter of this year."

Debt remains almost stable 
Total debt was 20.73 percent of total assets as on Dec. 31, 2016, compared with 20.62 percent on Dec. 31, 2015. Debt to equity ratio was at 0.56 as on Dec. 31, 2016, up from 0.49 as on Dec. 31, 2015.